Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 3No longer available 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 3Expanded_access 2

Sponsor

Cancer Type

CNS 5

Conditions

Glioma 4Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 44Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11durvalumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has announcements × TIC10 compound × Clear all
NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT03416530 2025-02-14

ONC201 in Pediatric H3 K27M Gliomas

Jazz Pharmaceuticals

Phase 1 Terminated
134 enrolled 1 FDA
CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

Jazz Pharmaceuticals

Phase 2 Terminated
84 enrolled 14 charts 1 FDA
CNS

Glioblastoma

NCT05392374 2022-05-26

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

NCT03134131 2022-03-14

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡